[RESEARCH BLOG] · 2026-09-11

RxSight, Inc. (RXST) – Sell Signal Amid Crisis‑Mode Market Regime and Deteriorating Fundamentals

By Pierre Brunelle · Founder & Research Lead

RXSTSELLCRISISsell flip

Lede: RxSight closed Thursday, 2026‑09‑10 at $5.96, a 5.85 % decline from the prior session, triggering a LOPJLB “SELL” directional signal with a –5 score as the market sits in a CRISIS regime.

Recent Catalysts

These items collectively illustrate a mix of institutional buying, conference exposure, analyst coverage, and mixed earnings outcomes that continue to shape market perception of RxSight.

Fundamentals and Valuation

RxSight’s valuation metrics paint a stark picture of a company struggling to translate its high‑margin product portfolio into sustainable earnings. The trailing twelve‑month (TTM) price‑to‑earnings ratio sits at ‑5.27, reflecting negative earnings and a market price that is effectively discounted against a loss‑making business. The enterprise‑value‑to‑EBITDA multiple mirrors this distress, standing at ‑5.64.

Balance‑sheet leverage is elevated, with a debt‑to‑equity ratio of 4.02, indicating that debt financing accounts for more than four times the equity base. The company’s book value per share remains modest, yielding a price‑to‑book (P/B) ratio of 0.94, just under parity with its net asset value.

Profitability metrics remain deeply negative. Return on invested capital (ROIC) is ‑10.41 %, while return on equity (ROE) and return on assets (ROA) are ‑17.35 % and ‑13.31 %, respectively. Gross margins are robust at 77.5 %, a testament to the high‑value nature of RxSight’s LALs, yet operating margins are ‑43.2 % and net margins ‑36.8 %, underscoring the heavy cost structure and ongoing R&D spend.

Analyst sentiment is muted. The consensus target price is $7.50, representing a modest upside of roughly 26 % from the current $5.96 level, but the prevailing recommendation is a Hold. Quality‑focused scores from LOPJLB place RxSight at 11.68 out of 100, while its growth score is 47.00, indicating that the market perceives upside potential despite the current financial strain.

MetricValue
P/E (TTM)‑5.27
EV/EBITDA‑5.64
P/B0.94
Gross Margin77.5 %
Operating Margin‑43.2 %
Net Margin‑36.8 %
Debt/Equity4.02
Analyst Target$7.50

Revenue and Earnings Trajectory

RxSight’s top‑line has grown rapidly over the past five years, expanding from $14.68 million in 2020 to a peak of $139.93 million in 2024, before slipping slightly to $134.48 million in 2025. This 3.9 % year‑over‑year decline in 2025 reflects a slowdown in new‑lens adoption amid heightened competition and pricing pressure from generic intraocular lens manufacturers.

Earnings per share (EPS) have been persistently negative since 2021, with a low of ‑$2.41 in 2022 and a modest improvement to ‑$0.71 in 2024. The 2025 EPS of ‑$0.95 suggests that while the loss per share narrowed relative to the 2022 trough, profitability remains elusive.

Free cash flow (FCF) has been a chronic drain. The company generated ‑$37.74 million in 2020, deepening to ‑$61.24 million in 2022, before partially recovering to ‑$19.39 million in 2025. The negative cash‑flow trend underscores the need for external financing or a decisive operational turnaround.

Operating efficiency has improved incrementally. Operating margins moved from ‑241.2 % in 2020 to ‑26.34 % in 2024, indicating that the firm is trimming overhead relative to revenue. However, the margin remains far from breakeven, and the net margin, though less negative at ‑19.62 % in 2024, still signals that the company is burning cash after accounting for all expenses.

ETF Ownership

While the data set does not list specific ETF holders for RxSight, the presence of large institutional purchases—most notably BlackRock’s multi‑million‑share acquisition—suggests that core healthcare or specialty‑device ETFs may hold modest positions. Concentrated ownership by a few heavyweight managers can amplify price volatility, especially when the broader market regime is in crisis mode. Investors should monitor any subsequent ETF rebalancing activity that could either cushion or exacerbate price swings.

LOPJLB Signal Read

The LOPJLB platform currently flags RxSight with a SELL directional signal, reflecting a composite score of ‑5. The underlying market regime is classified as CRISIS, a condition that historically coincides with heightened downside risk across the sector. Composite performance (PERF) is ‑7.10, while the quality‑focused FUND score stands at 11.68, placing the stock in the lower tier of the quality spectrum.

Value, growth, GARP, and quality scores are 12.00, 47.00, 6.80, and 11.68, respectively, painting a picture of a growth‑oriented but low‑quality company. The archetype is labeled Balanced, indicating that the stock does not fit cleanly into a pure value or pure growth category.

For a visual representation of the technical overlays that drive this signal—such as EMA crossovers, regime‑flip risk, and momentum accelerations—readers are encouraged to consult the interactive chart on the RxSight stock page. The full methodology behind LOPJLB’s scoring system is detailed at the LOPJLB methodology page.

Explore the full RxSight research suite:

The information presented herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consider their risk tolerance before making any investment decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

Open RXST signal detail → · Open screener → · Methodology